S&P 500   3,282.37 (+0.19%)
DOW   28,801.36 (+0.27%)
QQQ   222.32 (+0.39%)
AAPL   327.04 (+2.94%)
FB   223.64 (+2.69%)
MSFT   168.24 (+1.68%)
GOOGL   1,459.78 (+0.64%)
AMZN   1,866.25 (+0.70%)
CGC   23.65 (-1.13%)
NVDA   246.71 (-0.51%)
MU   55.57 (-1.59%)
GE   12.92 (+10.06%)
TSLA   584.25 (+3.06%)
AMD   47.49 (-6.04%)
T   37.24 (-3.47%)
ACB   1.94 (-1.52%)
F   8.89 (-1.00%)
NFLX   342.66 (-1.68%)
BAC   33.13 (-0.33%)
DIS   136.24 (-1.54%)
S&P 500   3,282.37 (+0.19%)
DOW   28,801.36 (+0.27%)
QQQ   222.32 (+0.39%)
AAPL   327.04 (+2.94%)
FB   223.64 (+2.69%)
MSFT   168.24 (+1.68%)
GOOGL   1,459.78 (+0.64%)
AMZN   1,866.25 (+0.70%)
CGC   23.65 (-1.13%)
NVDA   246.71 (-0.51%)
MU   55.57 (-1.59%)
GE   12.92 (+10.06%)
TSLA   584.25 (+3.06%)
AMD   47.49 (-6.04%)
T   37.24 (-3.47%)
ACB   1.94 (-1.52%)
F   8.89 (-1.00%)
NFLX   342.66 (-1.68%)
BAC   33.13 (-0.33%)
DIS   136.24 (-1.54%)
S&P 500   3,282.37 (+0.19%)
DOW   28,801.36 (+0.27%)
QQQ   222.32 (+0.39%)
AAPL   327.04 (+2.94%)
FB   223.64 (+2.69%)
MSFT   168.24 (+1.68%)
GOOGL   1,459.78 (+0.64%)
AMZN   1,866.25 (+0.70%)
CGC   23.65 (-1.13%)
NVDA   246.71 (-0.51%)
MU   55.57 (-1.59%)
GE   12.92 (+10.06%)
TSLA   584.25 (+3.06%)
AMD   47.49 (-6.04%)
T   37.24 (-3.47%)
ACB   1.94 (-1.52%)
F   8.89 (-1.00%)
NFLX   342.66 (-1.68%)
BAC   33.13 (-0.33%)
DIS   136.24 (-1.54%)
S&P 500   3,282.37 (+0.19%)
DOW   28,801.36 (+0.27%)
QQQ   222.32 (+0.39%)
AAPL   327.04 (+2.94%)
FB   223.64 (+2.69%)
MSFT   168.24 (+1.68%)
GOOGL   1,459.78 (+0.64%)
AMZN   1,866.25 (+0.70%)
CGC   23.65 (-1.13%)
NVDA   246.71 (-0.51%)
MU   55.57 (-1.59%)
GE   12.92 (+10.06%)
TSLA   584.25 (+3.06%)
AMD   47.49 (-6.04%)
T   37.24 (-3.47%)
ACB   1.94 (-1.52%)
F   8.89 (-1.00%)
NFLX   342.66 (-1.68%)
BAC   33.13 (-0.33%)
DIS   136.24 (-1.54%)
Log in

NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

$0.77
-0.03 (-3.75 %)
(As of 01/29/2020 03:08 PM ET)
Today's Range
$0.74
Now: $0.77
$0.79
50-Day Range
$0.34
MA: $0.52
$0.88
52-Week Range
$0.33
Now: $0.77
$1.20
Volume1,603 shs
Average Volume717,593 shs
Market Capitalization$26.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.06 per share

Profitability

Net Income$-6,780,000.00

Miscellaneous

Employees6
Market Cap$26.54 million
Next Earnings Date3/11/2020 (Estimated)
OptionableOptionable

Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter.


Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

How were Sophiris Bio's earnings last quarter?

Sophiris Bio Inc (NASDAQ:SPHS) released its quarterly earnings results on Friday, November, 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07). View Sophiris Bio's Earnings History.

When is Sophiris Bio's next earnings date?

Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Sophiris Bio.

What price target have analysts set for SPHS?

3 analysts have issued 1-year price objectives for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they expect Sophiris Bio's share price to reach $4.60 in the next year. This suggests a possible upside of 497.4% from the stock's current price. View Analyst Price Targets for Sophiris Bio.

What is the consensus analysts' recommendation for Sophiris Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio.

Has Sophiris Bio been receiving favorable news coverage?

News articles about SPHS stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sophiris Bio earned a news sentiment score of 3.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sophiris Bio.

Who are some of Sophiris Bio's key competitors?

What other stocks do shareholders of Sophiris Bio own?

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the folowing people:
  • Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 69)
  • Mr. Randall E. Woods, CEO, Pres & Director (Age 67)
  • Mr. Peter T. Slover, Chief Financial Officer (Age 44)
  • Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 56)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board

Who are Sophiris Bio's major shareholders?

Sophiris Bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.26%). View Institutional Ownership Trends for Sophiris Bio.

Which major investors are buying Sophiris Bio stock?

SPHS stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Sophiris Bio.

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.77.

How big of a company is Sophiris Bio?

Sophiris Bio has a market capitalization of $26.54 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.View Additional Information About Sophiris Bio.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is http://www.sophirisbio.com/.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]


MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel